Jaguar’s name is now Jaguar Health!

On Monday, July 31, the merger of Jaguar Animal Health and Napo Pharmaceuticals became effective. Napo focuses on the development and commercialization of proprietary gastrointestinal pharmaceuticals for the global human marketplace from sustainably derived plants used traditionally in rainforest areas. As a result of the merger, Jaguar’s name is now Jaguar Health, Inc., and Napo is a wholly-owned subsidiary of Jaguar, focused on the continuing commercialization of its Mytesi® (crofelemer) product, which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For noninfectious diarrhea in adults living with HIV/AIDS who are on ART*

Mytesi® is the ONLY FDA-approved diarrhea treatment that's been studied specifically in adults with HIV/AIDS1

Important Safety Information: MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). MYTESI® is not indicated for the treatment of infectious diarrhea. Read More...

Naturally derived health solutions for humans and animals around the world

In conjunction with Napo Pharmaceuticals, our wholly-owned subsidiary, Jaguar Health is focused on developing and commercializing a range of first-in-class gastrointestinal prescription products for humans and animals, as well as non-prescription gastrointestinal products for animals.

*IndicationMYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

*IndicationMYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).